ClinicalTrials.gg
RecruitingNCT04190589Updated Jan 7, 2026

Prospective Study of Extended Robotic Right Hemicolectomy With Complete Mesocolic Excision for Cancer

An interventional study of Robot-assisted laparoscopic extended right colectomy in Colorectal Cancer, sponsored by Vejle Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Vejle Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Colorectal Neoplasms by Vejle Hospital — 5 open to participants now, 6 under way, none of them phase 3. Colorectal Neoplasms · Vejle Hospital.

Planned enrollment
11th of 14
40 · median 77
Started
2020
with 1 other
No phase
5 of 17
3 open now
Registered
11th of 17
by date

Among the 17 studies in Colorectal Neoplasms by Vejle Hospital, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 with no phase, and was the 11th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 17 studies in Colorectal Neoplasms by Vejle Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Colorectal Neoplasms by Vejle Hospital, or all of them as a file.
02

Study summary

A single-center prospective study to elucidate whether extended robot-assisted right colectomy (e-RARC) performs as well as extended open right colectomy (e-ORC) in terms of specimen quality, and in addition, whether less postoperative morbidity and shorter length of stay (LOS) can be attained. Patients with colonic cancer near the right flexure or the oral part of the transverse colon will be compared excluding the most technically demanding and frail patients in both groups. A total of 40 patients undergoing e-RARC in a prospective series will be included and compared with 44 consecutive patients previously treated with e-ORC.

Read the detailed description

Complete mesocolic excision with central vascular ligation (CME) is an improvement of surgical technique in the operation for colonic cancer suggested to increase long-term survival. The concept was originally developed for open surgery by W. Hohenberger in Erlangen with excellent survival rates. However, if the tumor is located in the transverse colon or near the right colonic flexure, the procedure is particularly technically demanding, and for that reason most surgeons still prefer to do it by open operation (laparotomy) instead of the minimally invasive approach (laparoscopy) presently recommended for colonic cancer surgery. The advent of robotic surgery has improved the dexterity of instruments used in laparoscopic surgery and pushed the limits of what is possible with a minimally invasive approach. Since minimally invasive surgery is associated with better outcomes in terms of postoperative morbidity, pain, length of stay etc., it would be highly desirable if CME surgery could be done by robot-assisted laparoscopic operation instead of the current open approach. The current single-center study is proposed to elucidate whether extended robot-assisted right colectomy (e-RARC) performs as well as extended open right colectomy (e-ORC) in terms of specimen quality, and in addition, whether less postoperative morbidity and shorter length of stay (LOS) can be attained. Patients with colonic cancer near the right flexure or the oral part of the transverse colon will be compared excluding the most technically demanding and frail patients in both groups. A total of 40 patients undergoing e-RARC in a prospective series will be included and compared with 44 consecutive patients previously treated with e-ORC.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Robot
  • Hemicolectomy
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suspected or verified colonic cancer visualized by colonoscopy and on CT in the anal part of the ascending colon, in the right flexure or in the oral 2/3 of the transverse colon
  • Patient is 18 years or older, legally competent and able to comprehend information and give consent
  • Tumor is UICC stage I-III on preop CT
  • Operation is elective

Exclusion criteria

Exclusion Criteria:

  • Previous major open intraabdominal surgery
  • Ileus or other acute abdominal condition
  • CT scan with suspicion of T4 tumor
  • RITA score > 3 (Preop risk and frailty score)
  • > 35 kg/m2
  • Project surgeon not available
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Robotic CME

    Robot-assisted extended right colectomy

    Device: Robot-assisted laparoscopic extended right colectomy

Interventions

  • DeviceRobot-assisted laparoscopic extended right colectomy

    An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons

    Also known as: DaVinci Xi

06

What researchers measure

Primary outcomes

  1. Plane of dissection

    As judged by pathologist (mesocolic/intramesocolic/intramuscular)

    Time frame: 30 days

  2. Lymph node count

    Number of nodes in specimen, as determined by pathologist

    Time frame: 30 days

Secondary outcomes

  1. Complications

    Postoperative complications, graded by Clavien-Dindo

    Time frame: 30 days

  2. Reinterventions

    Reinterventions under anesthesia before discharge from hospital

    Time frame: 30 days

  3. Length of stay

    Days from operation to discharge from hospital

    Time frame: 30 days

  4. Readmissions

    Readmissions to hospital 1-30 days after initial discharge

    Time frame: 30 days

Other outcomes

  1. Operation time

    Minutes from first incision to final stitch

    Time frame: intraoperative

  2. Conversion rate

    Percentage of conversions from robotic to open surgery

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Dec 2026, 79 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 79 months is above that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 9, 2019
StartActual
May 18, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04190589
Lead sponsor
Vejle Hospital
Responsible party
Sponsor
First posted
Dec 9, 2019
Start date
May 18, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Hans B Rahr, MD DMSc
Contact
hans.rahr@rsyd.dk
+4520574529
Lars Bundgaard, MD
Contact
lars.bundgaard@rsyd.dk
+4579405618
Lars Bundgaard, MD
principal investigator · Department of Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion